In patients with atrial fibrillation who have experienced MI or undergone percutaneous coronary intervention (PCI), treatment with a combination of direct oral anticoagulants (DOACs) and dual antiplatelet therapy (DAPT) could significantly decrease the risk of bleeding and other major thromboembolic events, according to research published ahead of print in the Journal of the American College of Cardiology.

Emergency department visits for children with congenital heart disease (CHD) are getting more expensive over time but mortality rates are improving, according to an analysis of more than 420,000 CHD-related trips to the ED over a nine-year period.

Increases in tricuspid regurgitation (TR) severity occurred in 11.5 percent of patients following transvenous lead extraction, according to a single-center study, which also identified lead age as an important predictor of acute TR increases and tricuspid valve injury.

Cardiovascular risk factors have similar effects on the incidence of coronary heart disease (CHD) and ischemic stroke in women, researchers report in the first large-scale study of its kind in female patients.

A patient’s odds of surviving out-of-hospital cardiac arrest (OHCA) fluctuate an average of 56 percent from one emergency medical services (EMS) agency to another, researchers reported Sept. 26 in JAMA Cardiology.

Patients with peripheral artery disease (PAD) and a history of lower extremity revascularization (LER) face an increased risk of both cardiac and limb ischemic events and subsequent revascularization, according to research published in the Journal of the American College of Cardiology Oct. 2.

IRVINE, Calif., Sept. 26, 2018 — Edwards Lifesciences Corporation (NYSE: EW), the global leader in patient-focused innovations for structural heart disease and critical care monitoring, announced at a 60th anniversary educational event that the Every Heartbeat Matters initiative has exceeded the goal to impact the global burden of heart valve disease by supporting the education, screening and treatment of one million underserved people by 2020.

A Russian study that analyzed the process of blood coagulation in humans at different life stages has found hemostasis in newborn babies is particularly delicate—something that, paired with other common risks, can boost an infant’s risk of thrombosis early in life.